- Home
- CJET vs AYTU Comparison
CJET vs AYTU Comparison
Compare CJET & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- AYTU
- Stock Information
- Founded
- CJET 2009
- AYTU N/A
- Country
- CJET China
- AYTU United States
- Employees
- CJET N/A
- AYTU N/A
- Industry
- CJET Auto Manufacturing
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- AYTU Health Care
- Exchange
- CJET Nasdaq
- AYTU Nasdaq
- Market Cap
- CJET 11.0M
- AYTU 9.8M
- IPO Year
- CJET N/A
- AYTU N/A
- Fundamental
- Price
- CJET $2.01
- AYTU $1.41
- Analyst Decision
- CJET
- AYTU
- Analyst Count
- CJET 0
- AYTU 0
- Target Price
- CJET N/A
- AYTU N/A
- AVG Volume (30 Days)
- CJET 9.5K
- AYTU 36.9K
- Earning Date
- CJET 12-31-2024
- AYTU 02-12-2025
- Dividend Yield
- CJET N/A
- AYTU N/A
- EPS Growth
- CJET N/A
- AYTU N/A
- EPS
- CJET N/A
- AYTU N/A
- Revenue
- CJET $10,275,000.00
- AYTU $79,759,000.00
- Revenue This Year
- CJET N/A
- AYTU N/A
- Revenue Next Year
- CJET N/A
- AYTU N/A
- P/E Ratio
- CJET N/A
- AYTU N/A
- Revenue Growth
- CJET 31.31
- AYTU N/A
- 52 Week Low
- CJET $1.77
- AYTU $1.30
- 52 Week High
- CJET $30.00
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- CJET 47.19
- AYTU 34.74
- Support Level
- CJET $2.02
- AYTU $1.38
- Resistance Level
- CJET $2.07
- AYTU $1.70
- Average True Range (ATR)
- CJET 0.13
- AYTU 0.11
- MACD
- CJET -0.01
- AYTU -0.00
- Stochastic Oscillator
- CJET 25.88
- AYTU 16.22
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.